Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Dow
AstraZeneca
Cantor Fitzgerald
Citi
Harvard Business School
Queensland Health
Merck
Teva
Farmers Insurance

Generated: August 16, 2017

DrugPatentWatch Database Preview

Ani Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for ANI PHARMS, and what generic alternatives to ANI PHARMS drugs are available?

ANI PHARMS has one hundred and thirty-one approved drugs.

There is one US patent protecting ANI PHARMS drugs.

There are fourteen patent family members on ANI PHARMS drugs in eleven countries.

Summary for Applicant: Ani Pharms

Patents:1
Tradenames:73
Ingredients:67
NDAs:131
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ani Pharms Inc
PROPAFENONE HYDROCHLORIDE
propafenone hydrochloride
TABLET;ORAL076550-002Apr 23, 2004ABRXNoNo► Subscribe► Subscribe► Subscribe
Ani Pharms Inc
CIMETIDINE HYDROCHLORIDE
cimetidine hydrochloride
SOLUTION;ORAL074859-001Jul 9, 1998DISCNNoNo► Subscribe► Subscribe► Subscribe
Ani Pharms Inc
THIORIDAZINE HYDROCHLORIDE
thioridazine hydrochloride
TABLET;ORAL088272-001Apr 14, 1983DISCNNoNo► Subscribe► Subscribe► Subscribe
Ani Pharms Inc
FLUPHENAZINE HYDROCHLORIDE
fluphenazine hydrochloride
ELIXIR;ORAL081310-001Apr 29, 1993DISCNNoNo► Subscribe► Subscribe► Subscribe
Ani Pharms Inc
PURIFIED CORTROPHIN GEL
corticotropin
INJECTABLE;INJECTION008975-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Ani Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ani Pharms Inc
INDERAL LA
propranolol hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL018553-004Mar 18, 1987► Subscribe► Subscribe
Ani Pharms Inc
LITHOBID
lithium carbonate
TABLET, EXTENDED RELEASE;ORAL018027-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Ani Pharms Inc
INDERAL LA
propranolol hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL018553-002Apr 19, 1983► Subscribe► Subscribe
Ani Pharms Inc
BRETHINE
terbutaline sulfate
TABLET;ORAL017849-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Ani Pharms Inc
INDERAL LA
propranolol hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL018553-001Apr 19, 1983► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Ani Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,040,086Timed, sustained release systems for propranolol► Subscribe
9,358,214Timed, sustained release systems for propranolol► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ani Pharms Drugs

Country Document Number Estimated Expiration
Norway20041740► Subscribe
World Intellectual Property Organization (WIPO)03028708► Subscribe
South Korea20040084890► Subscribe
Austria442134► Subscribe
South Korea101090719► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Ani Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0062France► SubscribePRODUCT NAME: (A) DEXTROMETHORPHAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRATE DE DEXTROMETHORPHAN ET EN PARTICULIER LE MONOHYDRATE DE BROMHYDRATE DE DEXTROMETHORPHAN (B) QUINIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE SULFATE DE QUINIDINE EN PARTICULIER LE DIHYDRATE DE SULFATE DE QUINIDINE; REGISTRATION NO/DATE: EU/1/13/833/001-003 20130626
C/GB99/008United Kingdom► SubscribePRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
C0090France► SubscribePRODUCT NAME: SOLUTION D'IRRIGATION OCULAIRE COMPRENANT DE LA PHENYLEPHRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DU KETOROLAC OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/15/1018 20150728
13/055Ireland► SubscribePRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624
/2013Austria► SubscribePRODUCT NAME: KOMBINATION VON A) DEXTROMETHORPHAN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, BEISPIELSWEISE DEXTROMETHORPHANHYDROBROMID, UND INSBESONDERE DEXTROMETHORPHANHYDROBROMIDMONOHYDRAT UND B) CHINIDIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, BEISPIELSWEISE CHINIDINSULFAT, UND INSBESONDERE CHINIDINSULFATDIHYDRAT.; REGISTRATION NO/DATE: EU/1/13/833 20130626
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Dow
Farmers Insurance
Novartis
US Army
Argus Health
UBS
Covington
Boehringer Ingelheim
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot